Expression profile of microrna-145 in urothelial bladder cancer

Imagem de Miniatura
Arquivos
art_DIP_Expression_profile_of_microrna_145_in_urothelial_bladder_2013.PDF (211.55 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2013
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BRAZILIAN SOC UROL
Autores
Citação
INTERNATIONAL BRAZ J UROL, v.39, n.1, p.95-101, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: Bladder cancer (BC) is the second most common malignancy of the urinary tract, with high mortality. The knowledge of the molecular pathways associated with BC carcinogenesis is crucial to identify new diagnostic and prognostic biomarkers. MicroRNAs (miRNAs) are short non-coding RNA molecules that play important roles in the regulation of gene expression by acting directly on mRNAs. miR-145 has been considered as a tumor suppressor, which targets the c-MYC, MUC-1 and FSCN1 genes. Our aim was to evaluate the expression profile of miR-145 in low-grade non-invasive and high-grade invasive bladder urothelial carcinomas. Materials and Methods: We studied 30 specimens of low-grade, non-invasive pTa and 30 of pT2/pT3 high-grade invasive UC obtained by transurethral resection or radical cystectomy, followed over a mean time of 16.1 months. Normal controls were represented by five samples of normal bladder biopsy from patients who underwent retropubic prostatectomy to treat BPH. miRNA extraction and cDNA generation were performed using commercial kits. Analysis was performed by qRT-PCR, and miR-145 expression was calculated using the 2-(Delta Delta ct) method; we used RNU-43 and RNU-48 as endogenous controls. Results: miR-145 was under-expressed in 73.3% and 86.7% of pTa and pT2/pT3, respectively, with expression means of 1.61 for the former and 0.66 for the last. There were no significant differences in miR-145 expression and histological grade, tumor stage, angiolymphatic neoplastic invasion and tumor recurrence. Conclusion: miR-145 is under-expressed in low-grade, non-invasive and high-grade invasive urothelial bladder carcinoma and may play an important role in the carcinogenesis pathway, being an interesting candidate diagnostic marker.
Palavras-chave
MicroRNAs, MIRN145 microRNA, human [Supplementary Concept], Urinary Bladder, Diagnostic Techniques, Urological, Biological Markers
URI
https://observatorio.fm.usp.br/handle/OPI/3870
Referências
  1. Ambros V, 2003, CELL, V114, P269, DOI 10.1016/S0092-8674(03)00562-2
  2. Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
  3. Bakkar AA, 2003, CANCER RES, V63, P8108
  4. Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
  5. Blenkiron C, 2007, HUM MOL GENET, V16, pR106, DOI 10.1093/hmg/ddm056
  6. Borden LS, 2005, CURR OPIN ONCOL, V17, P275, DOI 10.1097/01.cco.0000156985.47984.9e
  7. Castillo-Martin M, 2010, UROL ONCOL-SEMIN ORI, V28, P401, DOI 10.1016/j.urolonc.2009.04.019
  8. Catto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744
  9. Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570
  10. Cimmino A, 2006, P NATL ACAD SCI USA, V103, P2464, DOI 10.1073/pnas.0510793103
  11. Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
  12. Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
  13. Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390
  14. Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384
  15. Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705
  16. Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
  17. Jemal A, 2011, CA CANC J CLIN, V61, P134
  18. Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
  19. Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
  20. Lin TX, 2009, J UROLOGY, V181, P1372, DOI 10.1016/j.juro.2008.10.149
  21. McConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008
  22. Michael MZ, 2003, MOL CANCER RES, V1, P882
  23. Ornitz DM, 1996, J BIOL CHEM, V271, P15292
  24. Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809
  25. Pandith AA, 2010, UROL ONCOL, V3
  26. Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106
  27. Sachdeva M, 2010, AM J TRANSL RES, V2, P170
  28. Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200
  29. Spizzo R, 2010, CELL DEATH DIFFER, V17, P246, DOI 10.1038/cdd.2009.117
  30. Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
  31. van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421
  32. Vignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013
  33. Wu XR, 2009, CANCER METAST REV, V28, P281, DOI 10.1007/s10555-009-9189-4

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55